prof jeannette lechner-scott - ms
TRANSCRIPT
MS Symposium – Rydges Newcastle 30 May 2019
1
Prof Jeannette Lechner-ScottHunter New England Local Health District
MS Symposium – World MS Day 30 May 2019
MS SymposiumCurrent Understanding of MS
Jeannette Lechner-Scott
John Hunter Hospital
May 2019
MS Symposium – Rydges Newcastle 30 May 2019
2
Topics
• Etiology
• Genetics
• Immunology
• New diagnostic criteria
• Risk factors for disease activity
• Novel therapies
• Differential diagnosis
Increasing prevalence and incidence of MS in young women
Ribbons K. et al. Mult Scler. 2017 Jul;23(8):1063-1071
MS Symposium – Rydges Newcastle 30 May 2019
3
Etiology
Genetics
MS Symposium – Rydges Newcastle 30 May 2019
4
Genetics
• HLA-DRB1*1501 main susceptibility factor (OR 3)
• HLA-A *02 decreases risk (OR -0.6)
• Presence of HLA-DRB1*1501 and absence of HLA-A*02 has an OR of 5
Genes affected by autoimmune disease
8
K K-H Farh et al. Nature 518, 337-347 2015
MS Symposium – Rydges Newcastle 30 May 2019
5
Nat Rev Neurol. 2017 Jan;13(1):25-36
Environmental risk factors
MS Symposium – Rydges Newcastle 30 May 2019
6
Interaction between smoking and genetic risk
factors
Hedstroem, Mult Scler 2019;25:180-
186
How does MS work
Jelcic et al., 2018, Cell 175, 85–100
MS Symposium – Rydges Newcastle 30 May 2019
7
Clinical symptoms
Subclinical degeneration
Time (years)
+
-
THERAPYAxonal dam
age
Disease course
2017 MS diagnostic criteria
14
Thompson, Lancet Neurol 2018
MS Symposium – Rydges Newcastle 30 May 2019
8
2017 MS diagnostic
criteria
15
Thompson, Lancet Neurol 2018
Lublin criteria
16
Neurology. 2014 Jul 15;83(3):278-86
MS Symposium – Rydges Newcastle 30 May 2019
9
Prognosishighly variable
Brain reserve
Stephen C. Krieger et al. Neurol Neuroimmunol Neuroinflamm 2016;3:e279
MS Symposium – Rydges Newcastle 30 May 2019
10
What can be done?
EARLY DIAGNOSIS
EARLY ACCESS TO EFFECTIVE
THERAPY
MS Symposium – Rydges Newcastle 30 May 2019
11
Effect of DMT on disability pension in Swedish registry
Brown W et al.JAMA. 2019 Jan 15;321(2):175-187
MS Symposium – Rydges Newcastle 30 May 2019
12
Predictors of progressionUher, Mult Scl January 2017Min M, Mult Scler. 2018 Oct;24(12):1569-1577Marrie RA, Mult Scler. 2015 Mar; 21(3): 263–281Tettey P Neuroepidemiology 2016;46:106-113
o Disability at baseline
o Brain atrophy
o Number of new lesion
o Age at onset
o Pyramidal or cerebellar symptoms at onset
o Obesity
o Co-morbidities
o Hypercholesterolemia
o Anxiety/depression
o smoking
19
94
19
96
20
00
19
98
20
02
20
04
20
06
20
08
20
10
20
12
20
14
20
16
20
18
AlemtuzumabTeriflunomide
Ocrelizumab Cladribine Tablets
sc IFN β-1b
im IFN β-1a
sc IFN β-1a
Natalizumab
Glatiramer acetate Fingolimod Daclizumab
Immunomodulation/immunostimulation
Chronic drug administration resulting in modulation of immune
function without immunosuppression
Clinical efficacy onlyduring active treatment
Selective, continuousimmunosuppression
Chronic drug administration resulting in ongoing suppression of
immune function
Clinical efficacy onlyduring active treatment
DMF
Broad spectrum immunosuppression
Prior to 1990s MS treatment options limited to
broad-spectrum immunosuppressants
Therapeutic evolution over the last 30y
DMF, dimethyl fumarate; IFN, interferon; im, intramuscular; sc, subcutaneous
24
Cyclophosphamide
Azathioprine
Therapies with potential for remission?
Short-course administration
Clinical efficacy extends well beyond period of active treatment
MS Symposium – Rydges Newcastle 30 May 2019
13
Disease modifying treatment
26
Relapses80%
relapse free
6-monthconfirmed EDSS
91% progression
free
NEDA44%
Active T262%
lesion free
T1 Gd+87%
lesion free
NEDA was defined as no relapses, no 6-month confirmed EDSS progression and no new T1 Gd+ lesions and no active T2 lesions on cranial MRI. Post hoc analysis EDSS, Expanded Disability Status Scale; Gd+, gadolinium-enhancing; NEDA, no evidence of disease activityGiovannoni G et al. Lancet Neurol 2011;10:329–37
MS Symposium – Rydges Newcastle 30 May 2019
14
Comparison of NEDA outcome over 2 years
0 5 10 15 20 25 30 35 40 45 50
Opera
CLARITY
Care MS I
AFFIRM
FREEDOMS
CARE MSII
beta IFN 1a in CARE
DEFINE/CONFIRM
TEMSO
% NEDA
% NEDA33%
37%
39%
27%
47%
32%
23%
23%
44%
Hauser ectrims 2015Giovannoni, Lancet Neurology 2011Nixon, Adv Therap 2014;31:1134Havdrova, Lancet Neurol 2009Havdrova, Therp Adv Neurol Dis 2014
Ocrelizumab
• Approved since October 2018
• Monoclonal antibody against B cells
• 6 monthly infusions of 600 mg
• Most common side effect infusion reaction
• First drug to show benefit in PPMS
• 3mCDP HR 0.76
• OBOE presented at AAN 2019
• LP in 99 patients
• Reduced B cells in CSF
• Reduced CXCL13
MS Symposium – Rydges Newcastle 30 May 2019
15
Cladribine
• Approved since January 2019
• Month one
• Oral tbl weight adjusted for 5d
• Month two
• Oral tbl weight adjusted
• Long lasting effect
• 75% stable for up to 4 y
• Well tolerated
• Crosses BBB
MS Symposium – Rydges Newcastle 30 May 2019
16
Malignancy risk
• Fingolimod
• Skin cancer BCC 272
• Breast cancer 168
• Multiple myeloma 132
• Cladribine
• Withdrawn from the market in 2012
• Meta-analysis of 11 studies showed no increased risk compared to other IS
• Alemtuzumab
• Lymphoma
• Thyroid carcinoma
• Natalizumab
• Incidence of melanoma 5/100 000 MS person years
• Breast cancers 375
• Melanoma 150
• CNS lymphoma
• Ocrelizumab
• Breast cancer
• Lymphoproliferative disorders
• ECTRIMS guidelines recommend regular FU while on IS
• annual dermatological screen recommended
• 3 annual pap smear independent of HPV
• Increased risk with high efficacy DMT HR of 4 (40/100,000)
• Vaccination recommended
• Annual breast screen
Lebrun-Rocher, CNS Drugs 2018; 32:939
Forest plot end malignancy RDs using Mantel-Haenszel pooling. CI, confidence interval; IFN, interferon; RD, risk difference 1. Dendrou CA et al. Nat Rev Immunol 2015;15:545–58; 2. Pakpoor J et al. Neurol Neuroimmunol Neuroinflamm 2015;2:e158. Figure adapted from reference 2
32
Malignancy risk in studies
Year Trial Drug Malignancy risk differences RD (95% CI) Weight (%)
2010 FREEDOMS Fingolimod −0.01 (−0.03, 0.00) 5.16
2012 CONFIRM Dimethyl fumarate −0.01 (−0.02, 0.00) 7.43
2006 SENTINEL Natalizumab −0.01 (−0.02, 0.00) 6.09
2011 TEMSO Teriflunomide −0.01 (−0.02, 0.00) 9.04
2012 CONFIRM Dimethyl fumarate −0.00 (−0.01, 0.00) 11.67
2012 CARE-MS II Alemtuzumab −0.00 (−0.02, 0.01) 5.39
2012 DEFINE Dimethyl fumarate −0.00 (−0.01, 0.01) 10.35
2013 TENERE Teriflunomide 0.00 (−0.01, 0.02) 4.61
2006 AFFIRM Natalizumab 0.00 (−0.00, 0.01) 9.37
2012 CARE-MS I Alemtuzumab 0.01 (−0.01, 0.02) 8.06
2010 TRANSFORMS Fingolimod 0.01 (0.00, 0.02) 9.56
Overall (I-squared=56.3%; p=0.009) −0.00 (−0.01, 0.00) 100.00
Note: Weights are from random effects analysis
Lower risk in treatment group
–0.02 –0.01 0 0.01 0.02
Lower risk in control group
MS Symposium – Rydges Newcastle 30 May 2019
17
Life style recommendations
Diet
• Roy Swank 1948• Low polysaturated fats
• OMS diet
• Terry Wahl• Raw foods, berry, fruits Paleo diet
• Rich in nutrients for mitochondria
• animal-based omega-3 fats, creatine, and coenzymeQ10, while your myelin needs vitamins B1, B9, B12, omega-3, and iodine
• Vitamin D
Cochrane Database Syst Rev. 2012 Dec 12http://www.msra.org.au/prevanzJagannath VA, Filippini G, Di Pietrantonj C, Asokan GV, Robak EW, Whamond L, Robinson SA. Vitamin D for the management of multiple sclerosis. Cochrane Database of Systematic Reviews. 2018(9).
Benefit of Vitamin D
• Jagannath VA, Filippini G, Di Pietrantonj C, Asokan GV, Robak EW, Whamond L, Robinson SA. Vitamin D for the management of multiple sclerosis. Cochrane Database of Systematic Reviews. 2018(9).
MS Symposium – Rydges Newcastle 30 May 2019
18
Differential diagnosis
• Neuromyelitis spectrum disorder
• 1804 Antoine Portal
• 1894 Devic
• 2004 Aquaporin 4 antibody
• astrocytopathy
• 2014 anti-MOG antibody
• Oligodendropathy
• 2019 3 controlled trials in NMOSD
• Eculizumab
• Complement C5 inhibitor
• Inebilizumab
• Monoclonal Ab CD 19
• Satralizumab
• Monoclonal antibody against IL6